Protocol I was a prospective Phase III randomized clinical trial (N=854) that compared intravitreal ranibizumab 0.5 mg + prompt (within 3–10 days) or deferred (after ≥24 weeks) laser versus sham intravitreal injection + prompt laser versus intravitreal triamcinolone 4 mg + prompt laser in treating DME. The post hoc analysis evaluated the relationship between the duration/extent of edema and long-term VA based on 3-year follow-up.